CRC
Clinical trials for CRC explained in plain language.
Never miss a new study
Get alerted when new CRC trials appear
Sign up with your email to follow new studies for CRC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets hard-to-treat cancers with RAS mutations
Disease control Recruiting nowThis study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 00:42 UTC
-
New drug cocktails take on Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies for people with advanced colorectal or pancreatic cancer. The goal is to see if these combinations are safe and can shrink tumors. About 1,130…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 00:40 UTC
-
New combo therapy targets advanced colorectal cancer
Disease control Recruiting nowThis study is testing a new drug called HCB101 combined with standard treatments for advanced or metastatic colorectal cancer. About 40 adults will receive weekly infusions to find the safest dose and see if the combination helps shrink tumors. The goal is to control the disease,…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated May 17, 2026 00:31 UTC
-
Gut bacteria cocktail could boost chemo for stage IV colon cancer
Disease control Recruiting nowThis study tests whether adding two antibiotics (ciprofloxacin and metronidazole) plus aspirin to standard chemotherapy can improve outcomes for people with stage IV colorectal cancer. About 97 participants will receive either chemo alone or chemo plus the microbiome therapy. The…
Matched conditions: CRC
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are closely monitored…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new type of CAR T cell therapy for adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that have lost a specific marker on their cells. The treatment uses the patient's own immune cells, modified to target cancer cells while protecti…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…
Matched conditions: CRC
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat colorectal cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called CBI-1214 in people with advanced colorectal cancer that has not responded to standard treatments. The drug works by helping the body's immune cells attack cancer cells. The main goals are to check safety and find the best dose, while…
Matched conditions: CRC
Phase: PHASE1 • Sponsor: Cartography Biosciences • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to shrink advanced colon tumors
Disease control Recruiting nowThis study tests a new drug combination (HS-20110) in about 500 adults with advanced colorectal cancer that has not responded to standard treatments. The goal is to find the safest and most effective dose and see if it can shrink tumors. Participants must have a specific type of …
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Smart CAR t cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…
Matched conditions: CRC
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New study gathers key materials for Next-Gen cancer therapy
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…
Matched conditions: CRC
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC